Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: A meta-analysis

被引：20

作者：

Liu S.-L. ^{[1
]}

Song Z.-F. ^{[1
]}

Hu Q.-G. ^{[1
]}

Shan D. ^{[2
]}

Hu S.-B. ^{[1
]}

Li J. ^{[1
]}

Zheng Q.-C. ^{[1
]}

机构：

[1] Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

[2] National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention

来源：

Frontiers of Medicine in China | 2010年 / 4卷 / 4期

关键词：

cholangiocarcinoma; prognostic factors; serum carbohydrate antigen 19-9;

D O I：

10.1007/s11684-010-0240-1

中图分类号：

学科分类号：

摘要：

This study was performed to determine the prognostic role of preoperative serum carbohydrate antigen (CA) 19-9 levels in the survival of patients with cholangiocarcinoma. Articles published up to June 1st, 2010 that evaluated preoperative CA19-9 levels and the prognosis of cholangiocarcinoma were collected for meta-analysis. The required information for calculating individual relative risk (RR) was extracted from the studies, and a combined overall RR was estimated. Nine eligible studies were included. One study dealt with extra-hepatic cholangiocarcinoma, while the other eight studies analyzed intra-hepatic cholangiocarcinoma. The mean methodological quality score was 74.1%, ranging from 65.5% to 82.5%. The overall RR for the nine studies was 1.28 (95% confidence interval = 1.10-1.46), and the Z-score for overall effect was 13.83 (P<0.001). The association between serum CA19-9 level and lymph node involvement was also assessed. The combined RR was 1.471 (95% confidence interval = 0.411-5.264) and Z-score for overall effect was 0.59 (P = 0.553). CA19-9 levels were associated significantly with the prognosis of patients with cholangiocarcinoma. This meta-analysis shows that elevation of preoperative CA19-9 levels is correlated with a poor prognosis of patients with cholangiocarcinoma. However, larger scale and randomized studies are needed to draw a more substantive conclusion. © 2010 Higher Education Press and Springer-Verlag Berlin Heidelberg.

引用

页码：457 / 462

页数：5

共 30 条

[1]

Blechacz B., Gores G.J., Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment, Hepatology, 48, 1, pp. 308-321, (2008)

[2]

Welzel T.M., McGlynn K.A., Hsing A.W., O'Brien T.R., Pfeiffer R.M., Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States, J Natl Cancer Inst, 98, 12, pp. 873-875, (2006)

[3]

Forsmo H.M., Horn A., Viste A., Hoem D., Evrebo K., Survival and an overview of decision-making in patients with cholangiocarcinoma, Hepatobiliary Pancreat Dis Int, 7, 4, pp. 412-417, (2008)

[4]

Heimbach J.K., Haddock M.G., Alberts S.R., Nyberg S.L., Ishitani M.B., Rosen C.B., Gores G.J., Transplantation for hilar cholangiocarcinoma, Liver Transpl, 10, 10 SUPPL. 2, (2004)

[5]

Heimbach J.K., Gores G.J., Haddock M.G., Alberts S.R., Nyberg S.L., Ishitani M.B., Rosen C.B., Liver transplantation for unresectable perihilar cholangiocarcinoma, Semin Liver Dis, 24, 2, pp. 201-207, (2004)

[6]

Uenishi T., Hirohashi K., Kubo S., Yamamoto T., Yamazaki O., Kinoshita H., Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma, Br J Surg, 88, 7, pp. 969-974, (2001)

[7]

Deoliveira M.L., Cunningham S.C., Cameron J.L., Kamangar F., Winter J.M., Lillemoe K.D., Choti M.A., Yeo C.J., Schulick R.D., Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann Surg, 245, 5, pp. 755-762, (2007)

[8]

Su C.H., Tsay S.H., Wu C.C., Shyr Y.M., King K.L., Lee C.H., Lui W.Y., Liu T.J., P'Eng F.K., Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma, Ann Surg, 223, 4, pp. 384-394, (1996)

[9]

Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B., Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, Jama, 283, 15, pp. 2008-2012, (2000)

[10]

Yusuf S., Peto R., Lewis J.A., Collins R., Sleight P., Beta blockade during and after myocardial infarction: an overview of the randomized trials, Prog Cardiovasc Dis, 27, 5, pp. 335-371, (1985)

← 1 2 3 →